Navigation Links
Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay
Date:2/25/2009

ROCKVILLE, Md., Feb. 25 /PRNewswire-USNewswire/ -- Adlyfe, a private company developing novel biomarkers and diagnostic tests for amyloid diseases, announced today that it has signed an agreement with Wyeth Pharmaceuticals, a division of Wyeth, to develop biomarker assays designed to measure levels of beta amyloid in the human brain. The companies will develop assays for specific beta amyloid targets for use in facilitating the development of treatments for Alzheimer's disease. The multiyear agreement included an upfront payment and specific future milestone payments. Further details of the agreement were not disclosed.

Chief Executive Officer Alan S. Rudolph, Ph.D., MBA said, "This agreement is a strong statement on the potential of Adlyfe's Pronucleon(TM) technology. This partnership will enable us to move faster in developing our assay, which could serve as an important tool in assessing the efficacy of amyloid-targeted therapies."

Burrill LLC served as financial advisor to Adlyfe in this transaction.

About Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive deterioration together with declining activities of daily living and neuropsychiatric symptoms or behavioral changes. It is the most common type of dementia. As the disorder progresses, cognitive impairment extends to the domains of language, skilled movements, recognition, and those functions closely related to the frontal and temporal lobes of the brain. This pathological process consists principally of neuronal loss or atrophy, principally in the temporoparietal cortex but also in the frontal cortex, together with an inflammatory response to the deposition of amyloid plaques and neurofibrillary tangles. According to the NIH's National Institute on Aging, as many as 5.5 million Americans presently suffer from Alzheimer's disease.

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases. Adlyfe is currently capitalized through generous investment from U.S. and international government sponsors and Burrill & Company and Canaan Venture Partners.

The Company's novel technology is based on the synthesis of small peptides, or Pronucleon(TM) peptides, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid aggregation (and eventual amyloid plaque formation). These aggregates are associated with disease state progression in a number of brain-wasting and amyloid diseases. Pronucleon(TM) peptides have also been shown to cross the blood brain barrier when administered intravenously in animals and image amyloid aggregates in the brain.

Internet Website: www.adlyfe.com


'/>"/>
SOURCE Adlyfe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
2. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
3. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
4. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
5. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
6. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
7. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
8. Personalized Medicine - The Genomic Revolution in Cardiac Care
9. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):